In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4+ and CD8+ T-cell epitopes for cancer immunotherapy

[1]  M. Subklewe,et al.  Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens , 2021, Cancer Immunology, Immunotherapy.

[2]  Sams M A Sadat,et al.  Potentiating Antigen Specific Immune Response by Targeted Delivery of the PLGA-Based Model Cancer Vaccine. , 2018, Molecular pharmaceutics.

[3]  J. Borst,et al.  CD4+ T cell help in cancer immunology and immunotherapy , 2018, Nature Reviews Immunology.

[4]  M. Nishimura,et al.  Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists , 2017, Cancer Immunology, Immunotherapy.

[5]  Yihui Deng,et al.  Nanoparticles for tumor immunotherapy , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[6]  Tian Zhang,et al.  Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy , 2017, Nature Nanotechnology.

[7]  Helen Y Wang,et al.  Immune targets and neoantigens for cancer immunotherapy and precision medicine , 2016, Cell Research.

[8]  Ian D. McGilvray,et al.  Mechanism of hard nanomaterial clearance by the liver , 2016, Nature materials.

[9]  Chun Wang,et al.  Hyaluronic Acid-Modified Cationic Lipid-PLGA Hybrid Nanoparticles as a Nanovaccine Induce Robust Humoral and Cellular Immune Responses. , 2016, ACS applied materials & interfaces.

[10]  G. Giannini,et al.  Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases. , 2016, Future medicinal chemistry.

[11]  Chintan H. Kapadia,et al.  Nanoparticulate immunotherapy for cancer. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[12]  R. Leighty,et al.  CD4+ T Cell Help Selectively Enhances High-Avidity Tumor Antigen-Specific CD8+ T Cells , 2015, The Journal of Immunology.

[13]  Y. Nishimura,et al.  Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses , 2015, Cancer science.

[14]  C. Löwik,et al.  Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[15]  O. Finn.  Vaccines for Cancer Prevention: A Practical and Feasible Approach to the Cancer Epidemic , 2014, Cancer Immunology Research.

[16]  A. Khurana,et al.  The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics , 2014, Front. Oncol..

[17]  F. Zunino,et al.  The potential of heparanase as a therapeutic target in cancer. , 2014, Biochemical pharmacology.

[18]  G. Gambaro,et al.  Heparanase as a target in cancer therapy. , 2014, Current cancer drug targets.

[19]  P. Coulie,et al.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy , 2014, Nature Reviews Cancer.

[20]  Pinghua Li,et al.  Resiquimod and polyinosinic–polycytidylic acid formulation with aluminum hydroxide as an adjuvant for foot-and-mouth disease vaccine , 2014, BMC Veterinary Research.

[21]  N. Restifo,et al.  Reassessing target antigens for adoptive T cell therapy , 2013, Nature Biotechnology.

[22]  K. Kaur,et al.  A simple approach for enhanced immune response using engineered dendritic cell targeted nanoparticles. , 2012, Vaccine.

[23]  V. Préat,et al.  PLGA-based nanoparticles: an overview of biomedical applications. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[24]  Vladimir Torchilin,et al.  Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance , 2012, Clinical Cancer Research.

[25]  C. Pisano,et al.  Significance of Heparanase in Cancer and Inflammation , 2012, Cancer Microenvironment.

[26]  Jun-Gu Guo,et al.  Multiple Antigenic Peptides Based on H-2Kb–Restricted CTL Epitopes from Murine Heparanase Induce a Potent Antitumor Immune Response In Vivo , 2012, Molecular Cancer Therapeutics.

[27]  D. Keskin,et al.  Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. , 2011, Biomaterials.

[28]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[29]  R. Schreiber,et al.  Natural innate and adaptive immunity to cancer. , 2011, Annual review of immunology.

[30]  C. Figdor,et al.  Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines. , 2011, Seminars in immunology.

[31]  B. Nelson,et al.  Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C). , 2011, Vaccine.

[32]  L. Sherman,et al.  CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. , 2010, Cancer research.

[33]  R. Sanderson,et al.  Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis , 2010, The FEBS journal.

[34]  Songtao Yu,et al.  Cytotoxic T lymphocyte epitopes from human heparanase can elicit a potent anti-tumor immune response in mice , 2010, Cancer Immunology, Immunotherapy.

[35]  A. Iwasaki,et al.  CTL mobilization to virus-infected tissue requires CD4+ T cell help , 2009, Nature.

[36]  S. Gringhuis,et al.  Signalling through C-type lectin receptors: shaping immune responses , 2009, Nature Reviews Immunology.

[37]  R. Noelle,et al.  Molecular mechanism and function of CD40/CD40L engagement in the immune system , 2009, Immunological reviews.

[38]  Songtao Yu,et al.  HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy. , 2008, Neoplasia.

[39]  Katrin Schwarz,et al.  Nanoparticles target distinct dendritic cell populations according to their size , 2008, European journal of immunology.

[40]  Songtao Yu,et al.  H-2Kb-restricted CTL epitopes from mouse heparanase elicit an antitumor immune response in vivo. , 2008, Cancer research.

[41]  S. Nie,et al.  Therapeutic Nanoparticles for Drug Delivery in Cancer , 2008, Clinical Cancer Research.

[42]  Sven Burgdorf,et al.  Endocytosis mechanisms and the cell biology of antigen presentation. , 2008, Current opinion in immunology.

[43]  E. Shpall,et al.  Dendritic cell immunotherapy for the treatment of neoplastic disease. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[44]  G. Parmiani,et al.  A listing of human tumor antigens recognized by T cells: March 2004 update , 2005, Cancer Immunology, Immunotherapy.

[45]  M. Bevan.  Helping the CD8+ T-cell response , 2004, Nature Reviews Immunology.

[46]  P. Robbins,et al.  A listing of human tumor antigens recognized by T cells , 2001, Cancer Immunology, Immunotherapy.

[47]  Helen Y Wang,et al.  Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling. , 2012, Advances in immunology.

[48]  H. Rammensee,et al.  Peptides naturally presented by MHC class I molecules. , 1993, Annual review of immunology.